Research Reports

Key takeaways

David E. I. Pyott (Class I director, Audit and Nominating Committees) retiring effective 2026 Annual Meeting, no disagreements.

Katharine Knobil, M.D. (Class II director, R&D Committee Chair, Nominating Committee) retiring effective Annual Meeting, no disagreements.

Suzanne Bruhn, Ph.D. (Class III director, Compensation and Nominating Committees) not standing for reelection, retiring effective Annual Meeting, no disagreements.

Board approved repricing of all pre-March 1, 2025 employee options to $1.33/share (Nasdaq close on April 17, 2026), including executives.

Repriced options require service through 12-18 month Retention Period to exercise at new price; reverts if terminated for cause or early voluntary exit.

Repricing aims to retain executives and employees without dilution or cash compensation amid all options underwater.

Full analysis

The simultaneous retirement of three directors from different classes and committees—Pyott (Class I), Knobil (Class II), and Bruhn (Class III)—signals potential Board refresh ahead of the 2026 Annual Meeting, with no disclosed disagreements ensuring continuity in governance perception. This impacts key oversight functions including audit, compensation, R&D, and nominations. Concurrently, the option repricing addresses underwater equity across all employees, including named executives Bernard Coulie (CEO), Keith Cummings (CFO), Lily Cheung (CHRO), and Minnie Kuo (COO), by resetting exercise prices to the April 17, 2026, closing price of $1.33. The Retention Period (18 months for exec leadership, 12 months for others) ties benefits to sustained service through critical periods or triggering events like corporate transactions, incentivizing alignment without new grants or cash outlays. Reversion clauses protect the company from early exits, balancing retention with risk mitigation.

PLRX · Pliant Therapeutics, Inc.

Summary

Key takeaways

Full analysis